TNFA - רווח נקי למניה (EPS TTM) TNF Pharmaceuticals Inc.

The lack of profitable assets forces TNF Pharmaceuticals (TNFA) to rely on investment capital. Business prospects depend on clinical trial outcomes and patent protection. A strategic alliance with biotech laboratories enhances the potential for mergers. The annual net income per share trend demonstrates capital dynamics, while the -255.99 indicator confirms the issuer's current level of fundamental stability.

For TNF Pharmaceuticals (TNFA), which develops molecular longevity technologies, net earnings per share serve as a key metric for measuring the efficiency of innovation capitalization. The rolling annual earnings per share figure demonstrates the portion of net income attributable to a single security over the last 12 months. This calculation neutralizes the impact of share issuances, highlighting the real growth in specific yield. For a biopharmaceutical investor, this is an indicator of the company's ability to monetize anti-aging research. A stable trend confirms the resilience of the business model regardless of quarterly fluctuations.